Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap.
Dynavax GmbH is the European affiliate of Dynavax Technologies Corporation USA, located in Düsseldorf, Germany. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and biopharmaceuticals.
Dynavax GmbH is led by an experienced management team with demonstrated expertise in vaccine and biopharmaceutical product development and manufacturing. Our success is seen through the production of recombinant proteins of our licensed technology platform.
Dynavax GmbH Employee Benefits
- Jobrad
- Recognition Awards
- Fitness Membership
- Flexible Working Hours
- Free Membership for Corporate Benefits
- Employee Breakfasts
- Christmas and Summer Parties
- Free Parking
-
Branche
-
Arzneimittelherstellung
-
Größe
-
51–200 Beschäftigte
-
Hauptsitz
-
Duesseldorf
-
Art
-
Kapitalgesellschaft (AG, GmbH, UG etc.)
